Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00292123
First received: February 14, 2006
Last updated: April 30, 2013
Last verified: December 2007
  Purpose

The primary goal of this study is to determine how contingency management can best be combined with standard or high doses of methadone to increase simultaneous abstinence from heroin and cocaine.


Condition Intervention Phase
Opioid Dependence
Cocaine Abuse
Drug: Methadone
Behavioral: Contingency Management
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Enrollment: 200
Study Start Date: June 1999
Study Completion Date: August 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Detailed Description:

A study of people pmaintained on Methadone using contingency management

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Opioid dependence; cocaine use

Exclusion Criteria:

  • Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00292123

Sponsors and Collaborators
Investigators
Principal Investigator: Kenzie Preston, PhD NIFA Intramural Research Program
  More Information

Publications:
Responsible Party: Kenzie L. Preston, Ph.D., Principal Investigator, National Institute on Drug Abuse
ClinicalTrials.gov Identifier: NCT00292123     History of Changes
Other Study ID Numbers: NIDAIRP 326
Study First Received: February 14, 2006
Last Updated: April 30, 2013
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on October 20, 2014